Answers About Board Games

jambot.comAn estimated 19.8 million Americans aged 40 and older were living with age-related macular degeneration, according to data from the Centers for Disease Control and Prevention, of which 1.49 million were at a risk of losing their vision.

The stock hit an over two-year high of $35.61 after the company released interim data on Saturday from the trial that tested the gene therapy, 4D-150, in patients with wet age-related macular degeneration (AMD), a leading cause of vision loss among older adults.

In the context of a severe patient population whose retinal thickness is 1.6 times above normal despite 10 prior injections over the last year, RBC Capital Markets analyst Lisa Walter said "you could not ask for a much better result."

Adverum and Regenxbio are also developing gene therapies for the disease, but BMO Capital Markets analyst Kostas Biliouris said Adverum's therapy has safety concerns, while the administration of Regenxbio's therapy is not convenient.

Wet AMD is a long-lasting disorder that causes blurred vision or a blind spot in the central vision due to fluid or blood leaking into the macula. budaya 4d Molecular's therapy was tested in 51 patients with severe disease that leads to thicker retinas, resulting in a high treatment burden as the patients have to depend on frequent injections such as Regeneron Pharmaceuticals' Eylea.